Workflow
总市值
icon
Search documents
中粮资本收盘下跌1.56%,滚动市盈率44.03倍,总市值291.47亿元
Sou Hu Cai Jing· 2025-07-25 08:54
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of COFCO Capital, noting a decline in stock price and profitability [1][2] - As of July 25, COFCO Capital's stock closed at 12.65 yuan, down 1.56%, with a rolling PE ratio of 44.03 times and a total market capitalization of 29.147 billion yuan [1] - The average PE ratio for the diversified financial industry is 42.44 times, with a median of 29.55 times, placing COFCO Capital at the 14th position within the industry [1][2] Group 2 - As of July 10, 2025, COFCO Capital had 136,000 shareholders, an increase of 10,000 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business focuses on the research and design of financial services, primarily offering trust investment products and insurance products [1] - In the latest quarterly report for Q1 2025, COFCO Capital reported operating revenue of 2.35 billion yuan, a year-on-year decrease of 8.74%, and a net profit of 392 million yuan, down 58.32%, with a gross profit margin of 52.97% [1]
ST景峰收盘上涨2.44%,滚动市盈率36.55倍,总市值51.73亿元
Sou Hu Cai Jing· 2025-07-25 08:30
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of ST Jingfeng, indicating a current stock price of 5.88 yuan with a PE ratio of 36.55 times, which is lower than the industry average of 61.55 times [1][3] - The company has a total market capitalization of 5.173 billion yuan, ranking 94th in the chemical pharmaceutical industry based on PE ratio [1][3] - Recent funding trends show a net inflow of 6.0358 million yuan on July 25, but a total outflow of 12.6988 million yuan over the past five days [1] Group 2 - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules, many of which are unique or under national medical insurance [2] - The company is actively expanding its product line and has several products that have received clinical approval or are in clinical research stages [2]
西山科技收盘上涨1.93%,滚动市盈率36.77倍,总市值30.98亿元
Sou Hu Cai Jing· 2025-07-24 12:15
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xishan Technology in the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 24, Xishan Technology's stock closed at 68.09 yuan, with a rolling PE ratio of 36.77, marking a new low in 61 days, and a total market value of 3.098 billion yuan [1] - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, positioning Xishan Technology at the 74th rank within the industry [1][2] Group 2 - The company specializes in the research, manufacturing, sales, and service of surgical medical devices, with key products including surgical power tools, endoscopic systems, and energy surgical equipment [1] - In the latest quarterly report for Q1 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66%, with a gross margin of 67.64% [1]
普门科技收盘上涨2.22%,滚动市盈率20.29倍,总市值59.22亿元
Sou Hu Cai Jing· 2025-07-24 12:15
Company Overview - Pumen Technology specializes in the research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The main products include medical products, home products, testing equipment, and testing reagents [2] Recent Achievements - In January 2024, Pumen Technology was awarded the "Smart Health and Elderly Care Application Pilot Demonstration - Demonstration Enterprise" by three ministries [2] - The project "Micro-tube Inner Surface Wear-resistant Superhydrophobic Coating and Its Application in Medical Devices" won the "2023 China Corrosion and Protection Society Science and Technology Award" first prize [2] - The subsidiary Guangdong Pumen Biomedical Technology Co., Ltd. was recognized as a "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprise" by the Guangdong Provincial Department of Industry and Information Technology [2] - A collaborative project with Chongqing University on "Key Technology Development and Industrialization of Fully Automatic Specific Protein Analyzer" received the "2023 China Industry-University-Research Cooperation Innovation Achievement Award" second prize [2] Financial Performance - In Q1 2025, the company reported revenue of 215 million yuan, a year-on-year decrease of 29.69% [2] - The net profit for the same period was 53.68 million yuan, down 49.93% year-on-year [2] - The sales gross margin stood at 64.97% [2] Market Position - As of July 24, Pumen Technology's stock closed at 13.82 yuan, with a PE ratio of 20.29, marking a new low in 63 days [1] - The company's total market capitalization is 5.922 billion yuan [1] - In comparison to the medical device industry, which has an average PE of 54.56 and a median of 37.54, Pumen Technology ranks 43rd [1][3] Shareholder Information - As of March 31, 2025, Pumen Technology had 13,289 shareholders, an increase of 3,464 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]
大东方收盘上涨2.01%,滚动市盈率73.50倍,总市值44.95亿元
Sou Hu Cai Jing· 2025-07-24 10:44
Group 1 - The core viewpoint of the articles highlights that Dazhong's stock closed at 5.08 yuan, with a PE ratio of 73.50, significantly higher than the industry average of 46.96 [1][2] - Dazhong's total market capitalization is reported at 4.495 billion yuan, ranking 35th in the medical services industry based on PE ratio [1][2] - The company has seen a decrease in the number of shareholders, with 82,560 shareholders as of March 31, 2025, down by 10,189 from the previous count [1] Group 2 - Dazhong's main business segments include department store retail, Sanfengqiao brand operations, and healthcare services [1] - The latest quarterly report for Q1 2025 shows a revenue of 921 million yuan, a year-on-year decrease of 8.55%, and a net profit of 39.93 million yuan, reflecting a significant year-on-year increase of 78.14% [1] - The company's gross profit margin stands at 19.46% [1]
国网英大收盘上涨1.46%,滚动市盈率18.07倍,总市值318.52亿元
Sou Hu Cai Jing· 2025-07-24 10:44
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Guo Wang Ying Da, which has a current stock price of 5.57 yuan, a PE ratio of 18.07, and a total market capitalization of 31.852 billion yuan [1][2] - The company operates in the diversified financial sector, which has an average PE ratio of 43.67 and a median of 30.27, placing Guo Wang Ying Da in 8th position within its industry [1][2] - As of the first quarter of 2025, three institutions hold shares in Guo Wang Ying Da, with a total of 580,500 shares valued at 0.03 million yuan [1] Group 2 - For the first quarter of 2025, Guo Wang Ying Da reported an operating income of 2.218 billion yuan, reflecting a year-on-year increase of 8.65%, and a net profit of 604 million yuan, which is a 45.22% increase year-on-year [1] - The company's gross profit margin stands at 13.45% [1] - The company primarily engages in a dual business model of "finance + manufacturing," covering areas such as trust, securities, futures, factoring, carbon assets, and power equipment [1]
万邦医药收盘上涨1.22%,滚动市盈率46.58倍,总市值31.53亿元
Sou Hu Cai Jing· 2025-07-24 10:27
Group 1 - The core viewpoint of the news is that Wanbang Pharmaceutical's stock performance shows a slight increase, but the company is experiencing a decline in revenue and profit compared to the previous year [1] - As of July 24, Wanbang Pharmaceutical's closing price is 47.3 yuan, with a PE ratio of 46.58, marking a new low in 33 days, and a total market capitalization of 3.153 billion yuan [1] - The company ranks 28th in the medical services industry, which has an average PE ratio of 46.96 and a median of 54.55 [1] Group 2 - In terms of capital flow, on July 24, there was a net inflow of 30,700 yuan, but over the past five days, the overall trend has been an outflow of 7.6469 million yuan [1] - Wanbang Pharmaceutical's main business is providing specialized pharmaceutical research outsourcing services, including clinical trial site management, biological sample analysis, data management and statistical analysis, prescription process research, quality research, and stability research [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 71.0522 million yuan, a year-on-year decrease of 21.20%, and a net profit of 11.8493 million yuan, a year-on-year decrease of 60.09%, with a sales gross margin of 31.62% [1] Group 3 - The PE ratios of other companies in the industry are as follows: WuXi AppTec at 22.35, Kanglong Chemical at 26.60, and others, with the industry average PE at 46.96 and the median at 54.55 [2] - The total market capitalization of the industry averages around 19.002 billion yuan, with Wanbang Pharmaceutical's market cap at 3.153 billion yuan [2] - The industry shows a range of PE ratios, with some companies like Aier Eye Hospital reaching as high as 33.61 [2]
东富龙收盘上涨2.65%,滚动市盈率71.48倍,总市值106.91亿元
Sou Hu Cai Jing· 2025-07-24 09:58
Company Overview - Dongfulong Technology Group Co., Ltd. specializes in providing pharmaceutical process, core equipment, and system engineering solutions for global pharmaceutical companies [1] - The main product segments include bioprocessing, formulation, overall engineering solutions, and food equipment engineering [1] Financial Performance - For Q1 2025, the company reported revenue of 1.137 billion yuan, representing a year-on-year increase of 2.58% [1] - The net profit for the same period was 20.1326 million yuan, showing a significant year-on-year decline of 68.87% [1] - The sales gross margin stood at 24.45% [1] Market Position - As of July 24, the closing price of Dongfulong was 13.96 yuan, with a PE ratio of 71.48, marking a new low in 139 days [1] - The total market capitalization of the company is 10.691 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 54.55, with a median of 37.54, placing Dongfulong at the 95th position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, only one institution holds shares in Dongfulong, which is a fund with a total holding of 2.1845 million shares, valued at 2.9 million yuan [1]
奥美医疗收盘上涨1.10%,滚动市盈率16.13倍,总市值58.26亿元
Sou Hu Cai Jing· 2025-07-24 09:30
Group 1 - The core viewpoint of the news highlights the current financial performance and market position of Aomei Medical, indicating a low PE ratio compared to the industry average [1][3] - As of July 24, Aomei Medical's stock closed at 9.2 yuan, with a PE ratio of 16.13, marking a 76-day low, and a total market capitalization of 5.826 billion yuan [1] - The medical device industry has an average PE ratio of 54.55, with Aomei Medical ranking 34th among its peers [1] Group 2 - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The company has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2] - In the first quarter of 2025, Aomei Medical reported a revenue of 759 million yuan, a year-on-year increase of 1.64%, while net profit decreased by 7.86% to 86.5 million yuan [3]
亚钾国际收盘下跌1.82%,滚动市盈率23.39倍,总市值293.29亿元
Sou Hu Cai Jing· 2025-07-24 08:43
Group 1 - The core viewpoint of the news is that Yara International's stock has experienced a decline, with a current price of 31.74 yuan and a rolling PE ratio of 23.39 times, which is below the industry average of 26.28 times [1][2] - Yara International's market capitalization stands at 29.329 billion yuan, ranking 16th in the fertilizer industry based on PE ratio [1][2] - The company has seen a net outflow of main funds amounting to 50.21 million yuan on July 24, with a total outflow of 220.81 million yuan over the past five days [1] Group 2 - Yara International's main business includes potassium salt mining, potassium fertilizer production, and sales, with key products being potassium chloride and brine [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 1.213 billion yuan, a year-on-year increase of 91.47%, and a net profit of 384 million yuan, a year-on-year increase of 373.53%, with a gross profit margin of 54.12% [1]